Overview
Indications
® KRYSTEXXA(pegloticase) is indicated, for the treatment of chronic gout in adult patients refractory to conventional therapy. Gout refractory to conventional therapy occurs in patients who have failed to normalize serum uric acid and whose signs and symptoms are inadequately controlled with xanthine oxidase inhibitors at the maximum medically appropriate dose or for whom these drugs are contraindicated.
Boxed Warning
FDA Black Box Warning
5.1 5.2 Anaphylaxis and infusion reactions have been reported to occur during and after administration of KRYSTEXXA. (,) 5.1 Anaphylaxis may occur with any infusion, and generally manifests within 2 hours of the infusion. However, delayed hypersensitivity reactions have also been reported. () 5.1 5.
Contraindications
When this intervention should not be used
KRYSTEXXA is contraindicated in: Warnings and Precautions (5.3) [see]. Patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency Patients with history of serious hypersensitivity reactions, including anaphylaxis, to KRYSTEXXA or any of its components.
Indications & Related Conditions
Conditions associated via SNOMED clinical relationships
Administration & Protocol
Dosing, route, and treatment protocol
Detailed dosage and administration information is available in the full FDA drug label.
View full prescribing information on DailyMedMonitoring & Follow-Up
Biomarkers relevant to this intervention via related conditions
No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.
Clinical Trials
25 trials linked to this intervention
Recent Trials
Efficacy of Proprietary Cherry Juice Blend in Osteoarthritis of the Knee
An Assessment of Chronic Synovial-Based Inflammation and Its Role With Serum Urate Levels.
Initiation of Allopurinol at First Medical Contact for Acute Attacks of Gout
Allopurinol Outcome Study
Efficacy and Safety of Colchicine for the Prevention of Gout Flares During the Initiation of Allopurinol
Research Evidence
Published studies and systematic reviews
Research data from MEDLINE/PubMed
Benefits & Expected Outcomes
Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.
Risks & Side Effects
Adverse reaction and safety data for this drug is sourced from the FDA-approved label.
View adverse reactions & drug interactions on DailyMedRelated Symptoms
Symptoms associated with conditions this intervention addresses
No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.
Alternatives & Comparisons
Alternative treatments, comparison data, and clinical decision support are pending physician authorship.
This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.
Do not start, stop, or change any treatment without consulting your healthcare provider.
Quick Facts
- Type
- Substance / Medication
- Fully Specified Name
- Pegloticase (substance)
- SNOMED CT
- 449280003
- UMLS CUI
- C2350656
- RxNorm CUI
- 1011650
- Labeler
- Horizon Therapeutics USA, Inc.
Clinical Data
This intervention maps to 1 entities in the Healos knowledge graph.
Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.